Guillen-Del-Castillo, AlfredoMeseguer, Manuel LópezFonollosa-Pla, VicentGimenez, Berta SáezColunga-Argüelles, DoloresRevilla-Lopez, EvaRubio-Rivas, ManuelRopero, Maria Jose CristoArgibay, AnaBarbera, Joan AlbertSalas, Xavier PlaMeñaca, Amaya MartínezVuelta, Ana Belen MadroñeroPadron, Antonio LaraComet, Luis SaezMorera, Juan Antonio DomingoGonzalez-Echavarri, CristinaMombiela, TeresaOrtego-Centeno, NorbertoGonzalez, Manuela MarínTolosa-Vilella, CarlesBlanco, IsabelSubias, Pilar EscribanoSimeon-Aznar, Carmen Pilar2023-05-032023-05-032022-03-11Guillén-Del-Castillo A, Meseguer ML, Fonollosa-Pla V, Giménez BS, Colunga-Argüelles D, et al. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. Sci Rep. 2022 Mar 28;12(1):5289. doi: 10.1038/s41598-022-09353-z. Erratum in: Sci Rep. 2022 Jul 28;12(1):12947.http://hdl.handle.net/10668/19596To assess severity markers and outcomes of patients with systemic sclerosis (SSc) with or without pulmonary arterial hypertension (PAH-SSc/non-PAH-SSc), and the impact of interstitial lung disease (ILD) on PAH-SSc. Non-PAH-SSc patients from the Spanish SSc registry and PAH-SSc patients from the Spanish PAH registry were included. A total of 364 PAH-SSc and 1589 non-PAH-SSc patients were included. PAH-SSc patients had worse NYHA-functional class (NYHA-FC), worse forced vital capacity (FVC) (81.2 ± 20.6% vs 93.6 ± 20.6%, P enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Familial Primary Pulmonary HypertensionHumansHypertension, PulmonaryLung Diseases, InterstitialPulmonary Arterial HypertensionScleroderma, Systemicresearch article35347225open accessEnfermedades pulmonares intersticialesHipertensión arterial pulmonarEsclerodermia sistémicaHipertensión pulmonar primariaHipertensión pulmonar10.1038/s41598-022-09353-z2045-2322PMC8960788https://www.nature.com/articles/s41598-022-09353-z.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960788/pdf